Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Forsyth

Showing results (391-400 of 406) with videos related to

Pageof 41
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 18, 2016
Clinical outcomes of melanoma brain metastases treated with stereotactic radiosurgery and anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitor, or conventional chemotherapyK A Ahmed, Y A Abuodeh, M I Echevarria, et al.
European Journal of Cancer (Oxford, England : 1990)|September 1, 2023
Stereotactic radiosurgery and anti-PD-1 + CTLA-4 therapy, anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitors, or conventional chemotherapy for the management of melanoma brain metastasesAmmoren E Dohm, Justyn Y Nakashima, Hruday Kalagotla, et al.
Breast Cancer Research and Treatment|October 20, 2021
The presentation of brain metastases in melanoma, non-small cell lung cancer, and breast cancer and potential implications for screening brain MRIsMatthew N Mills, Thrisha K Potluri, Yuki Kawahara, et al.
Neuro-Oncology|January 24, 2025
Phase II Trial of Brain MRI Surveillance in Stage IV Breast CancerKamran A Ahmed, Youngchul Kim, Avan J Armaghani, et al.
Bioorganic & Medicinal Chemistry Letters|January 5, 1999
Pyrroles and other heterocycles as inhibitors of p38 kinaseS E de Laszlo, D Visco, L Agarwal, et al.
Neuro-Oncology Advances|March 26, 2025
Phase 1 trial of hypofractionated stereotactic re-irradiation in combination with nivolumab, ipilimumab, and bevacizumab for recurrent high-grade gliomasSolmaz Sahebjam, Raju R Raval, Peter A Forsyth, et al.
Neuro-Oncology|May 27, 2026
Breaking Barriers in Leptomeningeal Disease: A SNO-ASCO Consensus Review on Clinical Trial Design and Basic Science IntegrationYolanda Piña, Maxine Umeh Garcia, Adrienne Boire, et al.
The New England Journal of Medicine|August 23, 2018
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the BrainHussein A Tawbi, Peter A Forsyth, Alain Algazi, et al.
Biorxiv : the Preprint Server for Biology|January 8, 2024
Branched-chain keto acids promote an immune-suppressive and neurodegenerative microenvironment in leptomeningeal diseaseMariam Lotfy Khaled, Yuan Ren, Ronak Kundalia, et al.
Journal for Immunotherapy of Cancer|April 28, 2025
Nivolumab and stereotactic radiosurgery for patients with breast cancer brain metastases: long-term results and biomarker analysis from a non-randomized, open-label, phase Ib studyKamran A Ahmed, Younchul Kim, Sungjune Kim, et al.
Pageof 41

Showing results (391-400 of 406) with videos related to

Sort By:
Pageof 41
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 18, 2016
Clinical outcomes of melanoma brain metastases treated with stereotactic radiosurgery and anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitor, or conventional chemotherapyK A Ahmed, Y A Abuodeh, M I Echevarria, et al.
European Journal of Cancer (Oxford, England : 1990)|September 1, 2023
Stereotactic radiosurgery and anti-PD-1 + CTLA-4 therapy, anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitors, or conventional chemotherapy for the management of melanoma brain metastasesAmmoren E Dohm, Justyn Y Nakashima, Hruday Kalagotla, et al.
Breast Cancer Research and Treatment|October 20, 2021
The presentation of brain metastases in melanoma, non-small cell lung cancer, and breast cancer and potential implications for screening brain MRIsMatthew N Mills, Thrisha K Potluri, Yuki Kawahara, et al.
Neuro-Oncology|January 24, 2025
Phase II Trial of Brain MRI Surveillance in Stage IV Breast CancerKamran A Ahmed, Youngchul Kim, Avan J Armaghani, et al.
Bioorganic & Medicinal Chemistry Letters|January 5, 1999
Pyrroles and other heterocycles as inhibitors of p38 kinaseS E de Laszlo, D Visco, L Agarwal, et al.
Neuro-Oncology Advances|March 26, 2025
Phase 1 trial of hypofractionated stereotactic re-irradiation in combination with nivolumab, ipilimumab, and bevacizumab for recurrent high-grade gliomasSolmaz Sahebjam, Raju R Raval, Peter A Forsyth, et al.
Neuro-Oncology|May 27, 2026
Breaking Barriers in Leptomeningeal Disease: A SNO-ASCO Consensus Review on Clinical Trial Design and Basic Science IntegrationYolanda Piña, Maxine Umeh Garcia, Adrienne Boire, et al.
The New England Journal of Medicine|August 23, 2018
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the BrainHussein A Tawbi, Peter A Forsyth, Alain Algazi, et al.
Biorxiv : the Preprint Server for Biology|January 8, 2024
Branched-chain keto acids promote an immune-suppressive and neurodegenerative microenvironment in leptomeningeal diseaseMariam Lotfy Khaled, Yuan Ren, Ronak Kundalia, et al.
Journal for Immunotherapy of Cancer|April 28, 2025
Nivolumab and stereotactic radiosurgery for patients with breast cancer brain metastases: long-term results and biomarker analysis from a non-randomized, open-label, phase Ib studyKamran A Ahmed, Younchul Kim, Sungjune Kim, et al.
Pageof 41